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A cyclic dtsulfide peptide representing anttgemc site A of foot-and-mouth-disease virus (FMDV) strain C-S8cl (residues 134 to 155 of viral protein 
1 (VPl) with Tyr”” and Arg’53 replaced by cystine; TTCTASARGDLAHLTTTHACHL) was synthesized by solid phase methods. Formation of 
the cychc disulfide was carried out by air oxidation of the fully deprotected and reduced bis-cysteine precursor. under high dilution conditions. 
The tdenttty of the cyclic peptide was confirmed by both physical and enzymatic methods. A conformattonal study of the cyclic pepttde and of 
its linear parent structure (YTASARGDLAHLTTTHARHLP. residues 136-156 of VP1 of FMDV C-S8cl) by circular dichroism m the presence 
of a structure-inducing solvent showed the cyclic disulfide analog to adopt lower levels of a-helix than its linear counterpart. In compettttve ELISA 
assays both peptides reacted with similar affinity agamst a representative panel of neutralizing monoclonal antibodies directed towards antigemc 
site A. Thus. a high inherent flexibthty of this loop may preclude a conformattonal restriction strong enough to alter recognition by anti-vtrus 
antibodies. 
Anttgenic pepttde; Conformational restriction: Circular dichrotsm; Monoclonal antibody; Solid phase peptide syntests 
1. INTRODUCTION 
Foot-and-mouth disease virus (FMDV) includes a 
major antigenic site (termed site A) involved in neutral- 
ization of infectivity, and located within amino acids 
135 to 160 of capsid protein VP1 [l-3]. The three-di- 
mensional structure of FMDV of serotype 0 (strain 
0,BFS) [4] showed that this region is a protein loop 
highly exposed on the capsid surface, with a diffuse 
density suggestive of high molecular disorder and flexi- 
bility. Only upon reduction of a disulfide bridge at the 
base of the loop a structure became apparent, but this 
segment remained one of the most mobile regions of the 
virus surface [5]. It has been proposed that, as with a 
peptide in solution, this loop may not have a unique 
conformation [6]. This could explain the relative success 
as synthetic vaccines of peptides mimicking this segment 
[3,8]. The loop could adopt, with little cost in free en- 
ergy, the conformations required to interact with many 
of the antibodies elicited against the homologous syn- 
thetic peptide. It has been also suggested that in FMDV 
0,BFS this loop exists at least in two spatial arrange- 
ments oriented towards different locations on the capsid 
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surface [9]. Such a change in orientation may also in- 
volve conformational alterations within the loop. 
For FMDV type C, linear peptides reproducing site 
A have been shown to be recognized almost as effi- 
ciently as the entire VP1 or complete virions by neutral- 
izing monoclonal antibodies (nMAbs) elicited against 
intact FMDV [lO,ll]. In addition. the effect of amino 
acid substitutions within site A on the recognition of 
intact virus by nMAbs directed to this site has been 
repeatedly reproduced with the corresponding substi- 
tuted peptides ([lo-121, Mateu et al., unpublished). 
These and other results [7] suggest that the antigenic site 
A of FMDV of serotype C is composed of continuous 
epitopes defined mainly by local conformation(s) within 
the VP1 G-H loop. However, some anti-FMDV type C 
MAbs recognized site A in the virus somewhat better 
than linear peptides representing the relevant sequence 
(Mateu et al., unpublished). Also, the immunogenicity 
of peptides reproducing site A is lower than that of the 
intact virus. Through many factors can account for this 
latter observation, an adequate conformational restric- 
tion may improve both the antigenicity and the immu- 
nogenicity of FMDV site A peptides. 
In many rival [13-151 and non-viral [16-181 proteins 
which depict well defined, structured epitopes, the spa- 
tial features of those sites have been mimicked by cyclic 
peptide structures with varying degrees of conforma- 
Published hi, Elsevirr Scrence Publishers B V 159 
Volume 328, number l,:! FERS LETTERS August 1993 
tional restriction more effectively than by linear pep- 
tides. For FMDV, the limited structural definition of 
site A is a serious drawback in designing constrained 
peptide models which could react better than linear site 
A peptides with anti-virus antibodies and thus become 
candidate synthetic vaccines. In this paper we describe 
the synthesis of a cyclic disulfide peptide defining a 
Is-residue (56-atom) loop corresponding to antigenic 
site A of FMDV C-S&l. We compare the reactivity of 
antibodies with this cyclic peptide and its linear counter- 
part. The similar reactivity of the two peptides suggests 
a considerable degree of structural flexibility of this 
segment. regardless of the disulfide bridge linking its 
ends. 
2. MATERIALS AND METHODS 
2.1. Peptlde .ywhe.m 
Solvents and reagents for sohd phase peptIde synthesis were as 
previously described [lo]. Automated peptIde synthesis was performed 
in an ABI 430A Instrument usmg Boc chemistry (manufact~lrer SSRC 
and stdl protocols for 0.1 and 0.5 mmol. respectively). with minor 
modifications. Manual couplmgs by the standard DCC procedure 
were performed as m [IO]. Couphngs mediated by benzotrlazol- 1 -yl- 
oxy-tris-(dnnethylammo)-phosphomum hexafluorophosphate (BOP) 
were performed by preincubatlon of Boc-ammo acid (0 4 M rn dimeth- 
ylformamide (DMF), 5 ml). BOP (1 M m DMF, 2 ml) and diisopro- 
pylethylamine (4 mmol, 680 &I) for 10 mm After assembly of the 
complete sequence. removal of the 2.4-dinitrophenyl (Dnp) HIS pro- 
tection and full deprotectlon and cleavage of the peptide resin by HF 
were performed as previouslq described [lo]. 
The crude linear peptide was purified m a medium-pressure CL8- 
silica column t~~chel~Miller. 30 x 300 mm) using a 15-2010 acetom- 
trde gradient in water (both solvents with 0 OS% trlfluoroacetlc acid 
(TFA)). The eluate was momtored at 220 nm and collected into ca. 
6-ml fractions which were analyzed by HPLC (Shlmadzu) on a Nucle- 
osil C,, column eluted with a linear 15-30% acetonitrile (+ 0.036% 
TFA) gradient into 0.045% TFA in water, and by HPCE (ABI 270A: 
fused silica 72 cm captllary. 50 cm to detector: SO,um i.d.) at 210 V/cm 
and 30°C m 20 mM citrate, pH 2.5 buffer. Fractions of the highest 
purity were pooled and re-run as above to gne material of satisfactory 
quality (> 97% by HPLC and HPCE). The purlfied linear peptide was 
diluted to 50pM with 0.02 M Tris-HCl buffer, pH 8. The solution uas 
vigorously stirred for 3-5 days at room temperature (r.t ) until oxida- 
tion was shown to be complete by HPLC. The reactlon was then 
quenched by addition of glacial HOAc to pH 3-4, lpophlhzed and 
desalted on Sephadex G-10 (2 x 100 cm) in 0.1 M HOAc. All pepttde 
fractions were of satisfactory purity (> 95%) by HPLC and HPCE and 
sere pooled and lyophilized. The purified cyclic disulfide peptlde was 
characterized by amino acid analysis (6 M HCI. 110°C. 24 h hydroly- 
sis; Beckman 6300 analyzer) and FAB-MS (VG Quattro, Fisons In- 
struments). Tryptic digests were performed on a 0 5 mg sample m 400 
,uI of 50 mM NH,HCO,, pH 8.4. treated with 20 ~1 of agarose-bound 
trypsin (80 U/ml, Sigma) for 120 mm at 37°C. The reactIon mixture 
was stopped by addition of glacial HOAc and centrifuged The super- 
natant was analyzed by HPLC using a linear 5-65% acetonitriie grad!- 
ent in water over 30 mm. Each peak was collected. analyzed for 
homogeneity by HPCE and submitted to ammo acid analysis, For 
DTT reductin, cyclic peptide (0.5 mg m 400~1 of 50 mM NH,HCO,, 
pH 8.4) was treated with 50 ,uI of 25 mM DTT ( I 10 x molar excess) 
in water for 2 h at 37°C. The reaction was quenched by HOAc and 
analyzed by HPLC and HPCE as above 
160 
Neutralizing MAbs raised agamst FMDV serotype C and which 
recognize site A have been previously described and their epitopes 
characterized 17, I I.201 Smear peptide (5 pmol. 100 ,uI) conjugated to 
KLH [21] was incubated overnight at 4°C as coating antigen m mi- 
crotiter plates. These were saturated for 2 h at r.t. with 5% BSA m 
PBS. and washed. Then, 100,~l ofa solutioncontaining a non-saturat- 
mg fixed amount of MAb premcubated for 1.5 h at r.t with different 
amounts of the competitor anttgcns t 1.6.5. 15,45, 135 and 405 pmol) 
m 1% BSA in PBS were added to the wells and further mcubated for 
I h at r.t After aashrng. 100 ,uI of peroxidase-conjugated goat-anti 
mouse IgG ( Bio-Rad. I :3000 dilutton 1 were added and incubated for 
I h at r.t.. followed by extensive washing. Bound antibody was de- 
tected using H,O, and 4-chloro-l-naphthol as substrate. The reactton 
was stopped with 100 ~1 of 4 N H,SO, and the absorbance at 492 nm 
read In a Tltertek multlscan photometer 
CD measurements were performed on a Jasco J720 spectropolan- 
meter flushed with N, (3 l/mm). Spectra were recorded at 5°C in a 1 0 
mm-pathlength cell contammg 20 ,uM peptide in 1 mM citrate. I mM 
phosphate, 15 mM NaCl buffer, pH 5 3 m the presence of varying 
amounts of hexafluoroisopropanol (HFIP). Data were typically col- 
lected usmg a 0.2 nm spectral bandwidth, a 4 s time constant (10 
nm/min) and averagmg the data from three scans 
2.5 Structurul utm$m n/ (7 c,lw pep/&e 
Molecular modellmg was performed on a Slhcon Graphics worksta- 
tlon using the INSIGHT II and DISCOVER programs. The mltlal 
conformatton was generated from the prevtously calculated lowest 
energy conformation of the nonapeptlde AC-TASARGDLA-NHMe 
[Z]. and appendmg to thts fragment the rematntng restdues of the 
sequence as a predetermtned s-helix This starting conformation Ras 
minimized using first the steepest descent method (500 iterations) and 
then the conjugate gradtent method (500 Iterations) The resulting 
conformation was subjected to IO ps molecular dynamics (MD) tryec- 
tory calculation at 750K. An integration step of 0 5 fs was used tn all 
the calculations. Durmg the tralectory. 20 structures were stored at 
regular times (0.5 ps) and minimized usmg the conjugate gradient 
algortthm until the norm of the gradient was less than 0.01 kcaUmo1. 
The last structure stored and minimized was newly subjected to the 
same MD trajectory calculation as above for a more effictent search 
of the confomlatlonal space. Solvent was not explicitly Included in the 
calculation but. m order to sunulate itb effect. a distance-dependent 
dlelectrtc constant of 4r was used 
3. RESULTS 
The cyclic disulfide model of the FMDV loop was 
designed on the basis of the reported X-ray diffraction 
structure of FMDV of serotype 0,BFS [4] and on ap- 
propriate alignment of site A sequences from serotypes 
0, and C, (Fig. I). The region between residues 134 and 
155 of VP1 was chosen, and since it has been suggested 
that the distance between the two C’ of residues Tyr”’ 
and Arg’“? in serotype 0, is ca. 10 A [23], the corre- 
sponding amino acids in the C, sequence (Tyr”” and 
Arg15’) were replaced by two cysteine residues to allow 
cyclization through an internal disulfide bridge. 
The linear precursor of the cyclic disulfide peptide 
(Fig. 1) was synthesized by solid phase methods [74] 
using Boc chemistry on p-methylbenzhydrylamine resin 
and the following side chain protections: Ser(Bz1). 
Thr( Bzl), Arg(Tos). His(Dnp), Asp(OcHex) and 
Cys(Meb). A first synthesis was done using rapid (30 
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dmrdered 
m,av Imp 
130 w w 160 
0,BFS 1860 . ..YNGGCRYSRNAVPNLRGDLQVLAPKVARTLP... 
130 156 
C-S8cl . ..YTGTTTYTASA...'RGDLAHLTTTHARRLP... 
Lmear peptIde H-YTASA~~~~RGDLAELTTTHARHLP-NH2 
Cyhc dnulflde peptldc H-TTCTASA....RGDLARLTTTHACHL-NH2 
I 
Fig. 1. Ammo acid sequence of the major antigenic site of FMDV 
0,BFS [4], of C-Sk1 [35]. and of synthetic pepttde models (hnear and 
cychc disulfide) of the latter vtrus A dot in the sequence indicates 
deletion of one amino acid. The double arrow above the sequence of 
FMDV 0,BFS spans the disordered region of the VP1 G-H loop of 
this vtrus [4], resolved upon reduction of the virion [5]. 
min/cycle) single couplings with symmetrical anhy- 
drides in DMF for all residues except Boc-Arg(Tos) and 
Boc-His(Dnp), which were coupled as HOBt esters. Thi- 
olytic Dnp removal, HF cleavage and purification led 
to a major product (fairly homogeneous by HPLC but 
later found heterogeneous by HPCE) the mass spectra 
of which showed two peaks (3:2 ratio) corresponding to 
the lack of one (M-101) and two (M-202) Thr residues, 
respectively. These results prompted a new synthesis of 
the linear precursor using longer coupling times (60 
min/average residue) and systematic recoupling of Thr 
residues, which were monitored by the Kaiser test. The 
problematic Thr couplings were found to be those of 
residues 134, 135 or 137, whereas the 148150 Thr trip- 
let was trouble-free. The ninhydrin test after recoupling 
of Thr13’ was still clearly positive and it was decided to 
carry out the rest of the synthesis manually. Standard 
DCC and DCC/HOBt couplings were again uneffective 
for this residue. which was only successfully coupled by 
A 
Fig. 2. Reverse-phase HPLC analysis of different stages of cychc 
dtsulfide formation. (A) reduced. purified hnear precursor, (B) after 
24-h oxtdation; and (C) fully oxtdized. purified by gel permeation 
chromatography. HPLC conditions, see text. 
136 I 153 
I I 
the BOP method [25]. Similar coupling difficulties at 
cys 3 
136 Thr135 and Thr’34 were solved likewise. Thiolytic 
Dnp removal [26] and HF acidolysis of the protected 
peptide resin gave a crude peptide that could be purified 
in two MPLC steps (global HF and purification yield 
27%) to an HPLC- and HPCE-homogeneous material 
(> 97%) with amino acid analysis and mass spectra con- 
sistent with theory. This linear peptide (5 x 10m4 M) was 
air-oxidized at pH 8. HPLC monitoring of the reaction 
(Fig. 2) showed the oxidation to be complete in 3-5 days 
for 7-10 pmol batches; for smaller samples, shorter 
times (1-2 days) sufficed. The oxidized material was 
remarkably clean and required only desalting to furnish 
the cyclic disulfide in high purity (95-97% by HPCE and 
HPLC, respectively). MS analysis gave a molecular 
peak two units less than the linear precursor. The inter- 
nal disulfide identity of this material was further con- 
firmed by a negative Ellman test [27] and by reversal to 
the reduced form upon treatment with DTT at pH 8.4 
(data not shown). Trypsin hydrolysis at the single Arg 
residue of the sequence afforded additional evidence in 
favor of the cyclic structure. As shown in Scheme 1, the 
cyclic disulfide yields a single tryptic product with the 
amino acid composition of the parent peptide, whereas 
other disulfide arrangements will produce more com- 
plex tryptic maps. Both HPCE (Fig. 3) and HPLC (not 
shown) tryptic maps gave a major component that did 
not coelute with either the starting cyclic disulfide or its 
reduced form and with an amino acid composition iden- 
tical to the parent sequence (Table I). MS analysis of 
this peak gave a molecular peak I8 units higher than the 
cyclic peptide. On the basis of this and the above evi- 
dence, it can be concluded that the oxidized material is 
indeed the desired cyclic monomeric form of the target 
peptide. Minor components of the tryptic digest (Table 
I) were attributed to lability of the disulfide under the 
alkaline proteolysis conditions. 
The conformational features of the cyclic disulfide 
were examined by CD and compared to those of a linear 
peptide. In HFIP titration experiments, the cyclic ana- 
Arg’44 
136 # 153 
I 2 I 
a trypsm 
&g’44 
Scheme 1 
161 
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i 
J 
Fig. 3. Capillary electrophoresis tryptic map of the cyclic disulfide 
peptide (I s vacuum injection, ca. 4 nl from a I ,~g/pl digestion mtx- 
ture). HPCE conditions. see text 
log showed -[&,& (negative molar ellipticity per res- 
idue at 222 nm) values consistently larger than its linear 
counterpart at any given HFIP concentration (Table 
II). Maximal helicity was reached at 14% HFIP for the 
linear peptide. whereas twice that amount was required 
by the cyclic analog to attain comparable, though still 
lower, a-helix levels. 
To evaluate the relevance of partial conformational 
restriction on the antigenic recognition by antibodies, 
both the linear peptide and its cyclic disulfide analog 
were tested in a competitive ELISA assay against a 
representative panel of eight nMAbs elicited against 
intact virus and directed towards distinguishable epi- 
topes within the VP1 G-H loop. The fully reduced linear 
precursor of the cyclic disulfide was used as a control. 
Results obtained with two MAbs (SD6 and 4C4) are 
presented in Fig. 4, and are representative of those ob- 
tained with the other six MAbs (5A2, 6Dl1, 7FCl2, 
7AHl and 7CAl1, [7]). These results showed that there 
were no significant differences in antigenic recognition 
between the linear and the cyclic forms. 
4. DISCUSSION 
The representation of B-cell continuous epitopes in 
linear peptides has as a main drawback the fact that 
such peptides exist in solution in a variety of random 
conformations, only a fraction of which may be recog- 
nized by protein-specific antibodies [28,29]. This is illus- 
trated by the fact that a large excess of peptide is often 
required to equal the antigenic reactivity of the native 
protein. Drawing from experience in the hormone-re- 
ceptor field [30], it has been suggested that appropriate 
conformational constraints may induce improved mo- 
lecular recognition between peptides and their cognate 
antibodies. Several examples of conformational restric- 
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Table I 
Tryptic fragments of disulfide cychc pepttde 
HPCE retention Abundance 
time’ 
Amino acid composition’ 
9.9 15% Asp,Thr,Gly,Ala,Leu,His, 
(C-termmal fragment) 
106 72% Asp,Thr,Ser,Gly,Ala,LeuiHls,Arg, 
(open sequence) 
I I.4 
12.2 
3% 
5% 
nd. 
Thr,Ser,Ala,Leu,Arg, 
(N-termmal fragment) 
13.6 
‘See Fig. 3 
5% nd. 
‘From the correspondmg HPLC-isolated fractions. Cys not deter- 
mmed 
tion by cyclization have been reported for influenza 
[13,14], hepatitis B [15], lysozyme [31] and FMDV [32] 
immunopeptides. Applying similar principles. we have 
sought to impose a conformational constraint on the 
G-H loop of serotype C of FMDV by means of an 
internal cyclic disulfide. To assess the severity of the 
conformational restriction, the cyclic structure was sub- 
jected to molecular dynamics to evaluate the distance 
between the two C” of the cystine residue and compare 
it with that reported for serotype 0,. This distance was 
measured in the three lowest energy conformers within 
3 kcal/mol and averaged according to Maxwell- 
Boltzman distribution at 278K to give a final value of 
5.6 A (vs. ca. 10 A for serotype 0,BFS). 
Examination of the conformational properties of the 
cyclic peptide by CD in HFIP-containing buffers re- 
vealed considerably lower levels of a-helix than its lin- 
ear counterpart. Maximal ellipticity values were almost 
50% larger for the linear than for the cyclic peptide, and 
were reached at lower concentrations of organic sol- 
vent. NMR studies (Roig et al., manuscript in prepara- 
tion) confirm the cl-helical character of the linear pep- 
tide in the presence of moderate amounts of HFIP. The 
VP1 G-H loops of FMDV serotypes 0 and A have also 
been described as helical on the basis of CD and NMR 
work on synthetic peptide models [32,33]. Assuming our 
Table II 
[&,& at different HFIP concentrations for hnear and cychc disulfide 
pepttdes 
HFIP% Linear Cychc disulfide 
0 -1.15 x IO’ -1.36 x IO’ 
4 -1.09 x IO3 -2 06 x IO’ 
8 -3.27 x IO’ -2.67 x IO’ 
I2 -1.70 x 10J -3.82 x 10’ 
I4 -1.92 x IO’ -7.49 x 102 
I6 -1.90 x IO” -1.13 x 10J 
20 -I 93 x 101 -1.27 x IO” 
28 n.d -1.43 x IO’ 
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SD6 
--fJ- Lmear peptide-KLH 
+ Lmear peptlde 
+ Cychc dwlflde pept& 
100 V Lmear d&f& pepsde ,oo 
* HRpepbde 
SO 80 
4 60 z&O 
0 T) 
S S 
g 40 B 40 
B B 
z 0 
20 +20 
0 0 
1 10 100 1000 1 10 100 1000 
competing agent (plcomole) competing agent (p~comole) 
Fig. 4. Inhibition of monoclonai antibody (SD4 and 4C4) binding to linear peptIde-KLH by different competing antigens in ELISA. Peptide HR, 
a 21-residue peptide with a replacement of HIS 146 by Arg that reproduces ite A of a vuus mutant which does not bind any Mab directed to this 
sate [7], and linear peptide conjugated to KLH were used as negative and positive controls, respectively. 
B 
linear peptide model of the VP1 loop to be helical under 
appropriate structure-inducing conditions, a possible 
interpretation for the observed loss in helical potential 
upon cyclization is given in Fig. 5, where the different 
effects of an internal constraint on two possible types 
of a-helical loop are compared. If the loop consists of 
an uninterrupted stretch of a-helix (A), it is not possible 
to draw together its two ends by cyclization without 
seriously disrupting its hydrogen bonding pattern, with 
a resulting decrease in the helical character. Alterna- 
tively, one can envisage a loop formed by two antiparal- 
lel stretches of a-helix (B), with lower amount of a-helix 
but where a covalent bond can be formed between the 
two ends without affecting the net helical content. The 
decrease in helicity observed by CD in going from the 
linear to the cyclic model of FMDV loop suggests that, 
while the former peptide is likely to exist as a continu- 
ously a-helical structure in the presence of HFIP (model 
A), the cyclic analog is more prone to adopt an arrange- 
ment such as model B, with a lower intrinsic helical 
content. This interpretation of CD data awaits further 
confirmation by ongoing NMR experiments. A previ- 
ous CD study on FMDV serotype A,, peptides [33] 
showed also some decrease in a-helix content upon 
cyclization. The VP1 G-H loop of FMDV O,BFS, as 
recently visualized by X-ray crystallography of DTT- 
treated v&ions, is partly helical [S]. However, since there 
is very low sequence similarity between the VP1 G-H 
Ftg. 5. Two possible arrangements of a helical Loop. In model A, 
considerable helix dtsruption is predtcted when the two ends of the 
loop are brought together by Internal cyclizatton. The helical content 
of B, lower than A, is however less affected by the internal constraint. 
163 
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loop of 0,BFS and C-S8cl -including a four amino acid 
deletion in the latter- it is not clear whether the structure 
of 0,BFS may apply to C-S8cl. 
The antigenic behavior of the conformationally re- 
stricted peptide towards a representative panel of 
nMAbs elicited against intact virus and directed to site 
A was essentially identical to that of its linear counter- 
part. In attempting to relate this finding with the CD 
results discussed above, lack of data on the effects of 
antibody binding on peptide conformation is a serious 
limitation. A relatively straightforward interpretation 
would be to assume that the disruption caused by cycli- 
zation, while substantial enough to be detectable by 
CD, does not reduce the flexibility of the peptide in the 
area of contact with antibodies to the extent that signif- 
icant recognition features are abolished. Cyclic disulfide 
peptides of small (6-residue) size have been shown to be 
rather flexible structures [34], and one should therefore 
expect considerably more flexibility for our 18-residue 
disulfide cycle. If confirmed by future results, such flex- 
ibility may in part defeat the purpose and eventual ap- 
plication of our approach. It should be noted, however, 
that in designing the present cycle an extrapolation of 
structural data from the 0,BFS to the C-SScl serotype 
was introduced (see section 3). Since the VP1 loops of 
the two serotypes are not of the same length (C-S8cl is 
four residues shorter), the possibility still remains that 
cychc peptides (disulfide or otherwise) of ring size 
slightly smaller than the present one are better recog- 
nized by MAbs than the linear peptides used so far and 
thus become improved models of the main antigenic site 
of FMDV. On the other hand, once it has been shown 
that a cyclic peptide model of this antigenic site is well 
recognized by nMAbs generated from FMDV, further 
work will be directed to assess the immunogenic poten- 
tial of such cyclic structures. 
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